5E91

TGF-BETA RECEPTOR TYPE 2 KINASE DOMAIN (E431A,R433A,E485A,K488A,R493A,R495A) IN COMPLEX WITH 3-AMINO-6-[4-(2- HYDROXYETHYL)PHENYL]-N-[4-(MORPHOLIN-4-YL)PYRIDIN-3-YL] PYRAZINE-2-CARBOXAMIDE


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.42 Å
  • R-Value Free: 0.242 
  • R-Value Work: 0.208 

wwPDB Validation 3D Report Full Report


This is version 1.1 of the entry. See complete history

Literature

Crystal structures of apo and inhibitor-bound TGF beta R2 kinase domain: insights into TGF beta R isoform selectivity.

Tebben, A.J.Ruzanov, M.Gao, M.Xie, D.Kiefer, S.E.Yan, C.Newitt, J.A.Zhang, L.Kim, K.Lu, H.Kopcho, L.M.Sheriff, S.

(2016) Acta Crystallogr D Struct Biol 72: 658-674

  • DOI: 10.1107/S2059798316003624
  • Primary Citation of Related Structures:  

  • PubMed Abstract: 
  • The cytokine TGF-β modulates a number of cellular activities and plays a critical role in development, hemostasis and physiology, as well as in diseases including cancer and fibrosis. TGF-β signals through two transmembrane serine/threonine kinase re ...

    The cytokine TGF-β modulates a number of cellular activities and plays a critical role in development, hemostasis and physiology, as well as in diseases including cancer and fibrosis. TGF-β signals through two transmembrane serine/threonine kinase receptors: TGFβR1 and TGFβR2. Multiple structures of the TGFβR1 kinase domain are known, but the structure of TGFβR2 remains unreported. Wild-type TGFβR2 kinase domain was refractory to crystallization, leading to the design of two mutated constructs: firstly, a TGFβR1 chimeric protein with seven ATP-site residues mutated to their counterparts in TGFβR2, and secondly, a reduction of surface entropy through mutation of six charged residues on the surface of the TGFβR2 kinase domain to alanines. These yielded apo and inhibitor-bound crystals that diffracted to high resolution (<2 Å). Comparison of these structures with those of TGFβR1 reveal shared ligand contacts as well as differences in the ATP-binding sites, suggesting strategies for the design of pan and selective TGFβR inhibitors.


    Organizational Affiliation

    Mechanistic Biochemistry, Bristol-Myers Squibb R & D, 311 Pennington Rocky Hill Road, Pennington, NJ 08534, USA.,Discovery Chemistry Oncology, Bristol-Myers Squibb R & D, PO Box 4000, Princeton, NJ 08543-4000, USA.,Protein Science, Bristol-Myers Squibb R & D, PO Box 4000, Princeton, NJ 08543-4000, USA.,Molecular Structure and Design, Bristol-Myers Squibb R & D, PO Box 4000, Princeton, NJ 08543-4000, USA.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
TGF-beta receptor type-2
A
316Homo sapiensMutation(s): 6 
Gene Names: TGFBR2
EC: 2.7.11.30
Find proteins for P37173 (Homo sapiens)
Go to Gene View: TGFBR2
Go to UniProtKB:  P37173
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
5L4
Query on 5L4

Download SDF File 
Download CCD File 
A
3-amino-6-[4-(2-hydroxyethyl)phenyl]-N-[4-(morpholin-4-yl)pyridin-3-yl]pyrazine-2-carboxamide
C22 H24 N6 O3
UEECNVFACUZGKV-UHFFFAOYSA-N
 Ligand Interaction
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.42 Å
  • R-Value Free: 0.242 
  • R-Value Work: 0.208 
  • Space Group: P 21 21 21
Unit Cell:
Length (Å)Angle (°)
a = 64.860α = 90.00
b = 75.770β = 90.00
c = 75.070γ = 90.00
Software Package:
Software NamePurpose
XDSdata reduction
PDB_EXTRACTdata extraction
AMoREphasing
BUSTER-TNTrefinement
Aimlessdata scaling

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History 

Deposition Data

  • Deposited Date: 2015-10-14 
  • Released Date: 2016-05-11 
  • Deposition Author(s): Sheriff, S.

Revision History 

  • Version 1.0: 2016-05-11
    Type: Initial release
  • Version 1.1: 2018-04-18
    Type: Data collection, Database references, Derived calculations